Inquiry Basket
Loading ......
Tumor cells and pathogens deploy different strategies to escape immune detection and destruction which allows them to survive and multiply within the host body through immune escape mechanisms. Through immune evasion techniques pathogens alter their antigenic properties to avoid detection while simultaneously disrupting immune cell signaling and activity. The process of immune escape involves multiple strategies which include antigen presentation interference and immunosuppressive factor secretion as well as microenvironment regulation combined with antigen camouflage and gene mutation and epigenetic modification. Tumor cells trigger immune escape mechanisms enabling them to evade detection by the immune system as they keep their ability to manage both viral and other pathogenic infections. Through detailed research into biological mechanisms scientists develop sophisticated immunotherapy treatments that enhance immune system reactions against both pathogens and tumor cells.
Tumor immune escape explains the process by which tumors cells deploy multiple techniques to evade immune system detection which allows them to survive and expand within the body. The development and spread of tumors depend on complex pathways involving genetic components, metabolic functions and alterations in the immune environment alongside inflammatory reactions. Tumors use multiple mechanisms to evade immune system detection as their primary escape method.Through downregulation and modification of tumor-associated antigen (TAA) expression tumor cells reduce immunogenicity which prevents detection and response from the immune system. Immunosuppressive molecules including PD-L1 checkpoint molecules produced by cancer cells stop T cell function and help the immune system evade detection. Immunosuppressive cells drawn toward tumor cells generate regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) which inhibit immune cell activity while enhancing immune tolerance. The tumor immune escape occurs when the immune microenvironment undergoes changes that include hypoxia and metabolic disturbances alongside acidic secretions which diminish immune cell performance. The killing ability and activation of T cells get reduced by tumor cells through decreased expression of MHC molecules which leads to lower levels of antigen presentation. Tumor cells develop immune tolerance which prevents immune system responses and shields them from immune system attacks. Tumor cells use several biological pathways to grow uncontrollably and avoid immune system detection. The research into mechanisms of tumor immune escape is essential for developing novel immunotherapies which include immune checkpoint inhibitors and CAR-T therapy.
Figure 1. ICIs combined with ADCs can produce synergistic effects in the treatment of urogenital tumors. (Sources: Yu P, et al. 2024)
The expression of MHC I molecules is often reduced or completely absent. Tumor cells suppress MHC I molecules which stops CD8+ T cells from identifying tumor antigens and this happens frequently across multiple cancer types including melanoma and colorectal cancer. This phenomenon can arise due to both genetic alterations and epigenetic control mechanisms. Genetic mutations in β2 - microglobulin genes and epigenetic modifications like DNA methylation disrupt MHC I molecule transcription and translation which compromises their functionality. Tumor cells disrupt the antigen processing and presentation (APM) pathway when they interfere with the MHC I molecule pathway by blocking the NLRC5 protein that is responsible for loading antigen peptides onto MHC I molecules thereby preventing T-cell recognition. Tumor cells boost levels of non-classical MHC I molecules such as HLA-G to avoid destruction by CD8+ T cells and NK cells. Tumor cells escape immune system detection because the tumor microenvironment with elements like hypoxia and immunosuppressive factors TGF-β and IL-10 alongside Tregs leads to reduced MHC I molecule expression. Disruptions in signaling pathways like IFN - γ pathway inhibition and JAK/STAT pathway abnormalities result in reduced expression of MHC I molecules. The degradation of MHC I molecules from the endoplasmic reticulum through autophagy and protein degradation mechanisms can be triggered by tumor proteins like SND1 which further diminishes their surface expression.
The tumor microenvironment contains various immunosuppressive factors. The cytokine IL - 10 constrains anti-tumor immune responses because it blocks T - cell activation while promoting B - cell proliferation. TGF-β controls Th1, Th2, and Th17 cell differentiation while establishing immune tolerance and enabling tumors to escape immune detection. IL - 4 drives Th2 cell differentiation while it blocks M2 - type MDSC development and enhances anti - tumor immune responses. IL - 35 which originates from Treg cells limits effector T cell activity to establish an immunosuppressive setting. PD - 1/PD - L1 inhibitory receptors stop T - cell activation which limits their tumor fighting abilities while CTLA - 4 blocking T - cell activation restricts their cancer attacking potential. The secretion of IL-10 and TGF-β by Myeloid-derived suppressor cells (MDSCs) acts to suppress T cell and NK cell activity while encouraging tumor expansion. Tumor-associated macrophages release VEGF and MMPs which lead to both angiogenesis and tumor growth. TGFβ and VEGF secretion by fibroblasts leads to tumor growth and immunosuppression. STING-related molecules activate the endoplasmic reticulum stress pathway for immunosuppression creation while nitric oxide (NO) adjusts immune cell functioning to facilitate tumor immune escape. Immunosuppressive factors combine through various processes to establish an immunosuppressive network within the tumor microenvironment which allows tumor cells to avoid immune system attacks while they grow and spread.
Through their essential regulatory function PD-1/PD-L1 checkpoint molecules enable tumor cells to avoid detection by the immune system. PD-1 operates as an immune checkpoint molecule present mainly on the surface of T cells whereas PD-L1 is extensively found on the surface of various tumor cells. The PD - 1/PD - L1 interaction obstructs T cell activation and proliferation and triggers effector T cell dysfunction and apoptosis which leads to tumor cells evading immune detection and destruction. Tumor cells boost PD-L1 levels to activate the PD-1/PD-L1 pathway that suppresses T-cell functions protecting themselves against immune system attacks. While the PD-1/PD-L1 pathway reduces tumor elimination as performed by the immune system it concurrently enhances tumor invasiveness and metastatic capabilities. Multiple cancer types including non-small-cell lung cancer (NSCLC), melanoma, and liver cancer develop abnormally via the PD-1/PD-L1 pathway. Nivolumab and pembrolizumab show substantial therapeutic results which explains their widespread adoption in cancer treatment to target the PD - 1/PD - L1 pathway. PD - 1 drugs block PD - L1 attachment which eliminates the T cell block enabling them to attack tumors. The effectiveness of treatment depends on tumor microenvironment factors and patient individuality while immune-related adverse reactions might develop.
The tumor microenvironment contains specific processes that stimulate regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Tregs release inhibitory molecules such as IL-10 and TGF-β which reduce the activity of effector T cells and NK cells to maintain immune tolerance. Through the PD-1/PD-L1 pathway Tregs establish connections with effector T cells resulting in diminished proliferation and functional activity of these cells. Tregs activate the expression of CTLA-4 and CD80/CD86 which suppresses antigen-presenting cells (APC) function and strengthens immunosuppression. The production of IL-10, TGF-β, and NO by MDSCs inhibits T cell and NK cell function while aiding tumor growth through angiogenesis and metastasis. When Tregs engage PD-L1 their immunosuppressive function becomes stronger and creates a positive feedback loop. MDSCs produce large amounts of Arg1 and NADPH oxidase (NOX) which convert L-arginine to L-ornithine and inhibit both T cell metabolism and proliferation. The PD-L1/PD-L2 and CD40/CD40L molecular interactions enhance immune suppression capabilities between Tregs and MDSCs. Tregs create IL - 10 and TGF - β that enhance MDSCs proliferation and functionality while MDSCs produce NO and ROS which enhance Tregs' suppression abilities. The chemokine CCL5 promotes interactions that result in cellular aggregation and enhanced function within tumor environments. Metabolic pathway exchanges between Tregs and MDSCs that involve glycolysis and NAD+ metabolism maintain immunosuppression within the tumor microenvironment. Adenosine receptors A2A and A2B along with CD73 work together to suppress T cell activity. Tumor progression is facilitated by immunosuppressive interactions between Tregs and MDSCs which obstruct anti-tumor immunity but also allow for new therapeutic approaches targeting PD-1/PD-L1 pathways.
Small molecule drugs combat tumor immune escape by targeting essential molecular processes in tumor cells and their surrounding environment to reestablish immune system recognition and destruction of tumors. The specific mechanisms are as follows:
Tumor cells modify their antigenic traits through irregular RNA editing processes like ADAR1p150 spliceosomes to evade detection by the immune system. ADAR1-mediated adenosine-to-inosine (A-to-I) RNA editing decreases the immune system's ability to detect tumor antigens. Selective use of Rebecsinib blocks ADAR1p150 activity which leads to proper antigen expression restoration in leukemia stem cells while maintaining hematopoietic stem cell function and extending animal survival rates.
Tumors avoid immune detection through primary epigenetic regulation disruptions. Decitabine functions as a DNA methylation inhibitor to reactivate genes related to tumor antigens which leads to enhanced CD8+ T cell anti-tumor responses while Vorinostat as a histone deacetylase inhibitor boosts T cell activation with increased expression of immune checkpoint molecules. Anti-tumor treatments demonstrate increased effectiveness when they are used alongside PD-1 antibodies.
Researchers continue to focus on PD-1/PD-L1 inhibitors as standard targets while new checkpoints like LAG-3, TIM-3, and TIGIT gain attention as research hotspots. LAG-3 inhibitors prevent T cells and NK cells from getting inhibited by blocking MHC-II binding while TIGIT inhibitors restore immune activation signals mediated by CD155/CD112.
Suppressive cells including Treg and MDSC along with factors like TGF-β and IL-10 function as "accomplices" enabling immune escape within the tumor microenvironment. STAT3/NF-κB pathway inhibitors decrease the production of these factors but targeted GLP-1 metabolic regulation drugs improve nutrient competition in the microenvironment which leads to better immune cell function. Latest research demonstrates that interfering with sphingolipid production can counter tumor immune evasion in KRAS mutant tumors while boosting immune cell destruction capabilities through increased interferon signaling.
Several specific small molecule drugs have been identified that reverse tumor immune escape using different mechanisms.
IDO1 functions as a fundamental enzyme that helps tumor cells avoid immune system attacks by disabling T cell activity. Research indicates that IDO1 inhibitors like 1-D-methyl-D-tryptophan (D-MET) and imidazole GDC-0901 (navoximod) decrease Treg cell quantities while boosting T cell performance which reverses tumor immune escape.
T cell suppression occurs because CD73 increases adenosine production in the tumor microenvironment. Research demonstrates that CD73 inhibitors like CBO421 decrease ADO concentration which activates dormant T cells to block tumor expansion and reverse immune escape.
Abnormal expression of FMRP in tumor cells prevents immune escape by blocking pro-inflammatory signals. Researchers are developing small molecule inhibitors of FMRP which should reverse tumor immune escape through immune response restoration.
The PTIR1 protein operates as an identical form to DDX58 and influences tumor cell antigen presentation alongside immune escape through control of deubiquitinase UCHL5. Research demonstrates that PTIR1 inhibitors enhance the immune system's response to tumors and reverse the tumors' ability to escape immune detection.
NKG2D ligand inducers activate NK cells to improve their tumor-killing capabilities which leads to a reversal of tumor immune escape.
STAT3 functions as a critical factor in tumor immune escape and its inhibitors improve anti-tumor immune responses through combined immune checkpoint inhibitor approaches.
The CD47/SIRPα signaling pathway enables tumor cells to hide from immune detection. Small molecule drugs that target this pathway result in tumor cell destruction through apoptosis and enhanced immune clearance by using monoclonal antibodies and additional small molecule drugs.
The immune evasion process allows pathogens and tumor cells to escape detection and destruction by the host immune system through diverse biological mechanisms. The evasion mechanisms consist of altering antigenicity along with the suppression of immune cell functions and the manipulation of immune signaling routes. Multiple mechanisms including interference with antigen presentation secretion of immunosuppressive factors and microenvironment regulation contribute to immune evasion. This component serves as a vital factor throughout the development of tumors and infections caused by viruses and other pathogens.
Multiple elements interact to create the complex process of tumor immune evasion. Antigen modulation which alters tumor-associated antigens tumor cells express immune suppressive molecules such as PD-L1 and recruit immune suppressive cells like Tregs and MDSCs while changing the immune microenvironment through hypoxia and metabolic disorders together with MHC molecule expression reduction and immune tolerance induction constitute the fundamental mechanisms of immune evasion. Researchers need to understand these mechanisms to create innovative immunotherapy approaches.
Tumor cells frequently lose or stop producing MHC I molecules which prevents CD8+ T cells from detecting tumor antigens. Gene mutations and epigenetic regulation defects as well as problems in antigen processing and presentation, over - expression of non - classical MHC I molecules, tumor microenvironment effects, signal transduction pathway changes, and autophagy/protein degradation processes can cause this phenomenon. A combination of these factors enables tumor cells to evade detection by the immune system.
The immune checkpoint molecule PD - 1 exists on T cells while PD - L1 shows high levels of expression across tumor cells. The PD-1 and PD-L1 binding process blocks T-cell activation and proliferation which causes effector T-cell function deterioration and supports tumor immune escape. Tumor cells increase the production of PD-L1 which blocks T-cell functions. Cancer treatments using immune checkpoint inhibitors that target this pathway show variable effectiveness because of the tumor microenvironment and patient-specific differences.
Small molecule drugs reverse tumor immune evasion through intervention in essential molecular processes. These drugs function by blocking abnormal targeted RNA editing while simultaneously regulating epigenetic modifications and immune checkpoint signals and remodeling the immunosuppressive microenvironment. IDO1 inhibitors together with CD73 inhibitors and FMRP inhibitors represent specific small molecule drugs that target crucial molecules and signaling pathways to reverse tumor immune escape within the tumor microenvironment.
References
Loading ......
